Journal of Rheumatic Diseases

Korean College of Rheumatology (대한류마티스학회)
권호 표지
DOI QR코드

DOI QR Code

Interleukin-32 Gamma as a New Face in Inflammatory Bone Diseases

  • Lee, Eun-Jin (Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Bongkun (Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hwang, Eui-Seung (Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Chang, Eun-Ju (Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2017.02.13
  • Accepted : 2017.02.14
  • Published : 2017.02.28
⟨ Previous Next ⟩

Abstract

Interleukin-32 (IL-32), a recently identified pro-inflammatory cytokine, is involved in the pathogenesis and progression of infections, cancer, chronic inflammation, and autoimmune disease. IL-32γ is the most active isoform in cell death and cell activation among nine distinct isoforms of IL-32. IL-32γ potentiates both osteogenic and osteoclastogenic capacities, and is critical in the coupling of bone resorption and bone formation for maintenance of bone homeostasis. IL-32γ is strongly associated with inflammatory bone disorders such as rheumatoid arthritis, ankylosing spondylitis, and osteoporosis. In this review, we summarize current research on the role of IL-32γ in inflammatory bone disorders, highlighting this cytokine as a novel target for prognostic marker and control of these diseases.

Keywords

Acknowledgement

This work was supported by grants from the Basic Science Research Program funded by the Ministry of Education, Science, and Technology (2016R1DA1B039-33855 and NRF-2014R1A1A2056099).